Dehydrodiisoeugenol是一种天然产物,具有抗炎和抗菌活性,可抑制小鼠巨噬细胞 (含LPS刺激) 中 NF-κB 活化和环氧合酶 (COX)-2 基因的表达。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | NF-κB ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ammonium pyrrolidine-1-carbodithioate | ✔ | 98% | |||||||||||||||||
| QNZ |
++++
NF-κB, IC50: 11 nM |
99%+ | |||||||||||||||||
| Sodium 4-Aminosalicylate Dihydrate | ✔ | 98% | |||||||||||||||||
| Sodium Salicylate | ✔ | 95% | |||||||||||||||||
| Parthenolide | ✔ | p53 | 97% HPLC | ||||||||||||||||
| JSH-23 |
+
NF-κB, IC50: 7.1 μM |
98% | |||||||||||||||||
| Phenethyl caffeate | ✔ | 98% | |||||||||||||||||
| Andrographolide | ✔ | 98+% | |||||||||||||||||
| Curcumin | ✔ | HDAC,Nrf2 | 98% | ||||||||||||||||
| SC75741 |
+++
NF-κB, EC50: 200 nM |
99%+ | |||||||||||||||||
| CBL0137 HCl |
++
NF-κB, EC50: 0.47 μM |
p53 | 99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | COX ↓ ↑ | COX-1 ↓ ↑ | COX-2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Piroxicam | ✔ | 98% | |||||||||||||||||
| Salicylic acid | ✔ | 98% | |||||||||||||||||
| Phenacetin | ✔ | 98% | |||||||||||||||||
| Etodolac | ✔ | 99% | |||||||||||||||||
| Flunixin meglumine | ✔ | 98% | |||||||||||||||||
| Ibuprofen L-lysine | ✔ | 98% | |||||||||||||||||
| Nabumetone | ✔ | 98% | |||||||||||||||||
| Acemetacin | ✔ | 98% | |||||||||||||||||
| Diflunisal | ✔ | 98% | |||||||||||||||||
| Pranoprofen | ✔ | 98% | |||||||||||||||||
| Ampiroxicam | ✔ | 98% | |||||||||||||||||
| Meloxicam | ✔ | 98% | |||||||||||||||||
| Sulindac | ✔ | 98% | |||||||||||||||||
| Ketoprofen | ✔ | 98% | |||||||||||||||||
| Mefenamic Acid | ✔ | 95% | |||||||||||||||||
| Bromfenac sodium | ✔ | 98% | |||||||||||||||||
| Oxaprozin | ✔ | 99% | |||||||||||||||||
| Aspirin | ✔ | 99% | |||||||||||||||||
| Nepafenac | ✔ | 98% | |||||||||||||||||
| Zaltoprofen | ✔ | 99% | |||||||||||||||||
| Salicin | ✔ | 98% | |||||||||||||||||
| Suprofen | ✔ | 99%+ | |||||||||||||||||
| Xanthohumol | ✔ | 99% | |||||||||||||||||
| Parecoxib | ✔ | 98% | |||||||||||||||||
| Tolfenamic Acid |
+++
COX-2, IC50: 0.2 μM |
98% | |||||||||||||||||
| Etoricoxib | ✔ | 99% | |||||||||||||||||
| Niflumic Acid | ✔ | 98% | |||||||||||||||||
| Valdecoxib |
++++
COX-2, IC50: 5 nM |
99+% | |||||||||||||||||
| Ibuprofen |
+
COX-1, IC50: 13 μM |
+
COX-2, IC50: 370 μM |
98% | ||||||||||||||||
| Indomethacin |
++
COX1, IC50: 0.28 μM |
+
COX-2, IC50: 14 μM |
97% | ||||||||||||||||
| Lornoxicam |
++++
COX-1, IC50: 5 nM |
++++
COX-2, IC50: 8 nM |
98% | ||||||||||||||||
| Meclofenamic acid sodium |
++++
COX-1, IC50: 40 nM |
+++
COX-2, IC50: 50 nM |
99% | ||||||||||||||||
| Asaraldehyde | ✔ | 98% | |||||||||||||||||
| Naproxen |
+
COX-1, IC50: 8.7 μM |
+
COX-2, IC50: 5.2 μM |
98% | ||||||||||||||||
| Diclofenac Sodium Salt |
+++
COX-1, IC50: 60 nM |
+++
COX-2, IC50: 200 nM |
98% | ||||||||||||||||
| NS-398 |
++
COX-2, IC50: 3.8 μM |
95% | |||||||||||||||||
| Amfenac Sodium Hydrate |
++
COX-1, IC50: 250 nM |
+++
COX-2, IC50: 150 nM |
98%+ | ||||||||||||||||
| Nimesulide |
+
COX-2, IC50: 26 μM |
98% | |||||||||||||||||
| Lumiracoxib |
++
COX-1, Ki: 3 μM |
+++
COX-2, Ki: 60 nM |
98% | ||||||||||||||||
| Rutaecarpine | ✔ | 95% | |||||||||||||||||
| Celecoxib |
++++
COX-2, IC50: 40 nM |
98% | |||||||||||||||||
| Carprofen |
++++
canine COX2, IC50: 30 nM |
98% | |||||||||||||||||
| Ketorolac |
++
COX-1 (human), IC50: 1.23 μM |
++
COX-2 (human), IC50: 3.50 μM |
98% | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Dehydrodiisoeugenol, a natural product isolated and purified from the seeds of Myristica fragrans Houtt. with anti-inflammatory activity, inhibits LPS-stimulated expression of the COX-2 in RAW264.7 murine macrophages and phosphorylation-dependent proteolysis of inhibitor IκB-α and transcriptional activity of NF-κB in the cells, and can cross the blood-brain barrier rapidly and might be one of the main bioactive substances of nutmeg. |
| Concentration | Treated Time | Description | References | |
| MCF-10A | 56.80 μM (IC50) | 48 h | No killing effect on normal breast epithelial cells | Front Pharmacol. 2025 Feb 28;16:1545498 |
| MCF-7 | 15.96 μM (IC50) | 48 h | Inhibited breast cancer cell proliferation by blocking the G0/G1 phase of the cell cycle | Front Pharmacol. 2025 Feb 28;16:1545498 |
| MDA-MB-231 | 14.98 μM (IC50) | 48 h | Inhibited breast cancer cell proliferation by blocking the G0/G1 phase of the cell cycle | Front Pharmacol. 2025 Feb 28;16:1545498 |
| NCM460 cells | 0.001-1000 μM | 48 h | The IC50 of DEH on NCM460 cells was significantly higher than that on HCT 116 and SW620 cells, indicating lower toxicity to normal cells. | J Exp Clin Cancer Res. 2021 Apr 10;40(1):125 |
| SW620 cells | 20, 40, 60 μM | 48 h | DEH significantly inhibited the proliferation and growth of SW620 cells by arresting the cell cycle at the G1/S phase. | J Exp Clin Cancer Res. 2021 Apr 10;40(1):125 |
| HCT 116 cells | 20, 40, 60 μM | 48 h | DEH significantly inhibited the proliferation and growth of HCT 116 cells by arresting the cell cycle at the G1/S phase. | J Exp Clin Cancer Res. 2021 Apr 10;40(1):125 |
| NCM460 human normal intestinal epithelial cells | 30 µM | Evaluate the impact of DDIE on cell viability, results showed no cytotoxicity within the tested concentration range | Acta Pharm Sin B. 2024 Dec;14(12):5286-5304 |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c mice | Subcutaneous tumor-bearing mouse model | Intraperitoneal injection | 40 mg/kg | Administered every other day for 2 weeks | DHIE significantly reduced tumor burden, decreased Ki-67 infiltration level, and inhibited PLK1 expression | Front Pharmacol. 2025 Feb 28;16:1545498 |
| NOD/SCID mice | CDX and PDX tumor xenograft models | Intraperitoneal injection | 40 mg/kg | Once every other day for two weeks | DEH significantly inhibited tumor growth in CDX and PDX models without affecting mouse body weight, indicating low toxicity. | J Exp Clin Cancer Res. 2021 Apr 10;40(1):125 |
| BALB/c mice | CPT11-induced gut mucositis model | Oral gavage | 25 and 75 mg/kg | Once daily for 12 days (Days 3–14) | Evaluate the protective effect of DDIE against CPT11-induced gut mucositis, results showed DDIE significantly alleviated weight loss, colon shortening, epithelial barrier dysfunction, goblet cells and intestinal stem cells (ISCs) loss, and promoted wound healing | Acta Pharm Sin B. 2024 Dec;14(12):5286-5304 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.06mL 0.61mL 0.31mL |
15.32mL 3.06mL 1.53mL |
30.64mL 6.13mL 3.06mL |
|
| CAS号 | 2680-81-1 |
| 分子式 | C20H22O4 |
| 分子量 | 326.39 |
| SMILES Code | OC1=CC=C(C2OC3=C(OC)C=C(/C=C/C)C=C3C2C)C=C1OC |
| MDL No. | N/A |
| 别名 | 去氢二异丁香酚 |
| 运输 | 蓝冰 |
| InChI Key | ITDOFWOJEDZPCF-AATRIKPKSA-N |
| Pubchem ID | 5379033 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(321.7 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1